Evidence map›Paper›PMID 40427560›Full record

ReviewBiomolecules2025

Senior-Loken Syndrome: Ocular Perspectives on Genetics, Pathogenesis, and Management.

Di Zhou, Yi Zeng, Weihan Luo, Chenyang Leng, Chen Li

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Di ZhouCenter for Drug Evaluation, National Medical Products Administration, Beijing 100076, China.
Yi ZengXiangya School of Medicine, Central South University, Changsha 410013, China.
Weihan LuoXiangya School of Medicine, Central South University, Changsha 410013, China.
Chenyang LengXiangya School of Medicine, Central South University, Changsha 410013, China.
Chen LiXiangya School of Medicine, Central South University, Changsha 410013, China.ORCID 0009-0002-3708-1476

Funding

National Natural Science Foundation of China 82170907
6 · The paper itself

Abstract

Senior-Loken syndrome (SLSN) is a group of rare autosomal recessive disorders caused by dysfunction of the primary cilium, primarily affecting the kidneys (typically leading to nephronophthisis) and eyes (typically leading to retinal degeneration). Moreover, patients with SLSN may experience additional multisystemic symptoms, such as developmental delay, intellectual disability, ataxia, and nystagmus. To date, eight genes have been demonstrated to cause SLSN, all encoding for proteins involved in the structure and functions of the primary cilium. This places SLSN within an expanding category of diseases known as "ciliopathies". Due to the genetic heterogeneity and significant phenotypic overlap with other ciliopathies, establishing a definitive diagnosis during the initial consultation remains a challenge for clinicians. Furthermore, current research on SLSN-related ciliopathies predominantly focuses on renal involvement, while the ocular manifestations remain insufficiently explored and lack a comprehensive review. Therefore, with the goal of offering practical guidance for clinical practice, this review aims to provide a comprehensive overview of the clinical features, along with an ocular perspective on the molecular mechanisms, genetic underpinnings, and advances in the treatment of SLSN.

Indexed as

CiliopathiesHumansKidney Diseases, CysticLeber Congenital AmaurosisOptic Atrophies, Hereditaryciliopathiesclinical featuresgenetic basisnephronophthisispathogenesisprimary ciliumretinal photoreceptorsSenior–Loken syndrometreatments

Identifiers

PMID40427560
PMCPMC12109206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.